Drugs / CD40.HIVRI.Env
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06665646 | Sep 2025 → Nov 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT04842682 | Mar 2021 → Nov 2024 | — | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD40.HIVRI.Env | “CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)” NCT04842682 ↗ |
| Known as | VRIPRO | “CD40.HIVRI.Env (VRIPRO)” NCT06665646 ↗ |
| Modality | Vaccine | “CD40.HIVRI.Env vaccination is safe and induced broad, potent and long-lasting anti-HIV immune responses recalled by a single late boost” PMID 42215520 ↗ May 2026 |
| Route | Subcutaneous | “CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)” NCT04842682 ↗ |
| Target | CD40 | “CD40-targeting vaccine” NCT04842682 ↗ |